Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2018-07
  • D-Luciferin (Potassium Salt): Gold Standard Substrate for...

    2026-02-01

    D-Luciferin (Potassium Salt): Gold Standard Substrate for In Vivo Bioluminescence Imaging

    Executive Summary: D-Luciferin (potassium salt) is the water-soluble form of D-Luciferin, serving as the preferred substrate for firefly luciferase in bioluminescence imaging (BLI) and reporter assays. Its high purity (>98%) and molecular weight (318.41 Da) make it suitable for sensitive tracking of tumor and stem cells in live animal models [APExBIO C3654]. In vivo imaging studies demonstrate robust signal, streamlined workflow, and low background compared to other forms. The potassium salt variant enhances experimental reproducibility by simplifying solution preparation and reducing pH variability [FireflyLuciferase.com]. It has become a critical reagent in studies evaluating cancer therapies, stem cell fate, and pathogen dissemination (Tao et al., 2025, DOI).

    Biological Rationale

    Bioluminescence imaging requires a substrate-enzyme pair that produces visible light in response to biological processes. D-Luciferin (potassium salt) is the substrate for Photinus pyralis (firefly) luciferase. This system is widely used in preclinical research to monitor gene expression, cell viability, and tumor progression [APExBIO C3654]. The potassium salt form improves water solubility (over 30 mg/mL at room temperature), allowing direct dissolution in physiological buffers without pH adjustment [Floxuridine.com]. This reduces handling errors and improves inter-experimental consistency.

    In vivo, D-Luciferin (potassium salt) crosses biological membranes and distributes rapidly after intraperitoneal or intravenous injection. It is especially suited for imaging in small animal models, such as mice and rats, due to its favorable pharmacokinetics and safety profile (Tao et al., 2025, DOI).

    Mechanism of Action of D-Luciferin (potassium salt)

    Firefly luciferase catalyzes the oxidation of D-Luciferin in the presence of ATP, Mg2+, and O2 to generate oxyluciferin, AMP, CO2, and visible light (peak emission: 560 nm). The reaction is highly specific—only D-isomer of luciferin acts as a substrate; the L-isomer is inactive. The potassium salt enhances substrate solubility, ensuring rapid and uniform bioavailability after administration. The light produced is proportional to the amount of luciferase present, which enables quantitative assessment of reporter gene expression or cell number [Dual-Luciferase.com]. The emission spectrum (yellow-green) penetrates mammalian tissues efficiently, supporting deep-tissue imaging.

    Evidence & Benchmarks

    • In vivo bioluminescence imaging with D-Luciferin (potassium salt) enables detection of 103–104 luciferase-expressing cells per mouse, with a signal-to-noise ratio >100:1 (Tao et al., 2025, DOI).
    • Compared to the free acid form, the potassium salt dissolves in water within 1 minute at 25°C, eliminating the need for alkaline buffers (APExBIO, product data).
    • Luciferase reporter assays using D-Luciferin (potassium salt) exhibit coefficient of variation (CV) <5% across technical replicates in 96-well format (APExBIO, product data).
    • Preclinical oncology models use D-Luciferin (potassium salt) to monitor tumor growth and assess therapeutic efficacy of radiotherapy and chemotherapeutics (Tao et al., 2025, DOI).
    • In ATP quantification, the substrate provides a linear response over 6 orders of magnitude (10 fmol–10 nmol ATP) (APExBIO, product data).

    Applications, Limits & Misconceptions

    D-Luciferin (potassium salt) is validated for:

    • In vivo bioluminescence imaging (BLI): Enables longitudinal tracking of luciferase-labeled cells in living animals.
    • Luciferase reporter assays: Used in promoter activity studies, pathway analysis, and high-throughput screening.
    • ATP assays: Quantifies cellular energy status or microbial contamination.
    • Stem cell and tumor cell tracking: Facilitates fate mapping and therapy evaluation.

    For a broader perspective on mechanistic insights and epigenetic applications, see D-Luciferin (Potassium Salt): Expanding the Horizon of Bioluminescence Imaging—this article adds updated benchmarks and directly references the 2025 radiotherapy study.

    Common Pitfalls or Misconceptions

    • Not active with non-firefly luciferases: D-Luciferin (potassium salt) does not work with Renilla, Gaussia, or NanoLuc luciferases.
    • Photostability limits: Solutions are light-sensitive and should be protected from ambient light to minimize substrate degradation.
    • Solution storage: Aqueous solutions are unstable; use freshly prepared solutions for maximal activity.
    • pH sensitivity: While the potassium salt is more robust, extreme pH can still affect luciferase activity.
    • Not a direct cell viability assay: Bioluminescence reflects luciferase expression, not viability unless coupled to an appropriate promoter.

    For troubleshooting and advanced best practices, D-Luciferin Potassium Salt: Powering Bioluminescence Imaging focuses on troubleshooting and workflow optimization, while this article incorporates new evidence from radiotherapy sensitization studies.

    Workflow Integration & Parameters

    Recommended storage: -20°C, desiccated, protected from light. Typical working concentrations: 100–200 mg/kg (in vivo, i.p. injection); 150–300 μg/mL (in vitro). Prepare solutions in sterile water or PBS; avoid repeated freeze-thaw cycles. Inject substrate 10–15 min prior to imaging for optimal tissue distribution [Floxuridine.com]. For high-throughput assays, batch preparation under subdued light is advised.

    This article extends D-Luciferin (Potassium Salt): Illuminating Precision Strategies by providing quantitative workflow parameters validated in the context of recent brain metastasis imaging studies.

    Conclusion & Outlook

    D-Luciferin (potassium salt) from APExBIO (SKU C3654) remains the gold standard for quantitative BLI in translational research. Its performance is validated in oncology, stem cell, and infection models, including recent studies on radiotherapy response in brain metastasis (Tao et al., 2025). Future innovations may focus on further improving tissue penetration and reducing signal attenuation. For product details or ordering, visit D-Luciferin (potassium salt) at APExBIO.